RAAS activation is a prominent feature of ADPKD pathophysiology and ACE inhibitor therapy in children with ADPKD and borderline hypertension has been shown to prevent GFR decline and left ventricular mass index (LVMI) increase that otherwise occurs with disease progression. The gene discussed is ACE; the disease is autosomal dominant polycystic kidney disease.